RU2734076C2 - Антитела, направленные на cd127 - Google Patents
Антитела, направленные на cd127 Download PDFInfo
- Publication number
- RU2734076C2 RU2734076C2 RU2016151265A RU2016151265A RU2734076C2 RU 2734076 C2 RU2734076 C2 RU 2734076C2 RU 2016151265 A RU2016151265 A RU 2016151265A RU 2016151265 A RU2016151265 A RU 2016151265A RU 2734076 C2 RU2734076 C2 RU 2734076C2
- Authority
- RU
- Russia
- Prior art keywords
- seq
- antibody
- disease
- antigen
- cells
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5418—IL-7
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462010117P | 2014-06-10 | 2014-06-10 | |
| US62/010,117 | 2014-06-10 | ||
| EP15305078.6A EP2955196A1 (en) | 2014-06-10 | 2015-01-23 | Antibodies directed against CD127 |
| EP15305078.6 | 2015-01-23 | ||
| PCT/EP2015/062993 WO2015189302A1 (en) | 2014-06-10 | 2015-06-10 | Antibodies directed against cd127 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016151265A RU2016151265A (ru) | 2018-07-18 |
| RU2016151265A3 RU2016151265A3 (enExample) | 2019-02-08 |
| RU2734076C2 true RU2734076C2 (ru) | 2020-10-12 |
Family
ID=52434718
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016151265A RU2734076C2 (ru) | 2014-06-10 | 2015-06-10 | Антитела, направленные на cd127 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10428152B2 (enExample) |
| EP (2) | EP2955196A1 (enExample) |
| JP (2) | JP7324565B2 (enExample) |
| KR (1) | KR102612930B1 (enExample) |
| CN (1) | CN106715471B (enExample) |
| AP (1) | AP2016009599A0 (enExample) |
| AU (1) | AU2015273532C1 (enExample) |
| BR (1) | BR112016028755B1 (enExample) |
| CA (1) | CA2950823A1 (enExample) |
| CL (1) | CL2016003172A1 (enExample) |
| CR (1) | CR20160576A (enExample) |
| EA (1) | EA039303B1 (enExample) |
| HK (1) | HK1231487A1 (enExample) |
| IL (1) | IL249449B (enExample) |
| MA (1) | MA40202A (enExample) |
| MX (1) | MX376066B (enExample) |
| MY (1) | MY190889A (enExample) |
| NZ (1) | NZ726932A (enExample) |
| PE (1) | PE20170324A1 (enExample) |
| PH (1) | PH12016502445A1 (enExample) |
| RU (1) | RU2734076C2 (enExample) |
| SA (1) | SA516380455B1 (enExample) |
| SG (1) | SG11201610036PA (enExample) |
| TN (1) | TN2016000528A1 (enExample) |
| UA (1) | UA125366C2 (enExample) |
| WO (1) | WO2015189302A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6362543B2 (ja) | 2012-02-23 | 2018-07-25 | ジュノ セラピューティクス ゲーエムベーハー | 細胞および他の複雑な生物学的材料のクロマトグラフィーによる単離 |
| EP2955196A1 (en) * | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
| KR102789821B1 (ko) | 2015-03-31 | 2025-04-02 | 소리소 파마슈티컬스 인크. | 프로테아제-절단가능 링커를 갖는 펩티드 구조물 |
| JP2018511346A (ja) | 2015-03-31 | 2018-04-26 | ブイエイチスクエアード リミテッド | ポリペプチド |
| US11466253B2 (en) | 2015-10-22 | 2022-10-11 | Juno Therapeutics Gmbh | Methods for culturing cells and kits and apparatus for same |
| WO2017125578A1 (en) | 2016-01-21 | 2017-07-27 | Vhsquared Limited | Polypeptides |
| KR102819051B1 (ko) * | 2016-02-29 | 2025-06-12 | 오제 이뮈노테라프틱스 | Ｉｌ７ 수용체 세포외 도메인의 알파 쇄에 대해 지시된 비-길항성 항체 및 암 치료에 있어서 이의 용도 |
| US11098128B2 (en) * | 2016-12-09 | 2021-08-24 | Ose Immunotherapeutics | Antibodies and polypeptides directed against CD127 |
| WO2019043065A1 (en) * | 2017-08-29 | 2019-03-07 | Ose Immunotherapeutics | METHOD AND PREPARATION FOR SORTING T EFFECTOR LYMPHOCYTES USING ANTI-CD127 ANTIBODIES FOR CELL THERAPY APPLICATIONS |
| CN110117325B (zh) * | 2018-03-09 | 2023-06-20 | 重庆市畜牧科学院 | 一种猪cd127多肽及其编码基因和应用 |
| EP3914622A1 (en) | 2019-01-22 | 2021-12-01 | Bristol-Myers Squibb Company | Antibodies against il-7r alpha subunit and uses thereof |
| BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
| EP3986571A1 (en) * | 2019-06-21 | 2022-04-27 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| CN114514243B (zh) | 2019-06-21 | 2025-01-24 | 索瑞索制药公司 | 多肽 |
| EP3986570A1 (en) | 2019-06-21 | 2022-04-27 | Sorriso Pharmaceuticals, Inc. | Compositions |
| CN110894237B (zh) * | 2019-12-05 | 2021-08-03 | 山东省分析测试中心 | 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用 |
| AU2021262748A1 (en) * | 2020-04-27 | 2022-12-01 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting CD127 and use thereof |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| WO2022251253A1 (en) | 2021-05-24 | 2022-12-01 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| US20220389104A1 (en) * | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
| ES3023172T3 (en) * | 2022-05-30 | 2025-05-30 | Ose Immunotherapeutics | Biomarkers of il7r modulator activity |
| CN115925955B (zh) * | 2022-12-30 | 2025-09-26 | 浙江正熙生物技术有限公司 | 一种抗cd127抗体及其制备方法和应用 |
| CN121002069A (zh) | 2023-01-06 | 2025-11-21 | 泰温治疗私人有限公司 | 抗原结合分子 |
| EP4455308A1 (en) | 2023-04-24 | 2024-10-30 | Les Laboratoires Servier | Il-7r gene signatures |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| IL327045A (en) | 2023-10-05 | 2026-05-01 | Capstan Therapeutics Inc | Structure-restricted ionizable cationic lipids and lipid nanoparticles |
| AU2024365145A1 (en) * | 2023-10-26 | 2026-05-07 | National Cancer Center | Antibody against interleukin-7 receptor (il-7r), and antibody-drug conjugate (adc) including said antibody |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025202213A1 (en) | 2024-03-26 | 2025-10-02 | Institut National de la Santé et de la Recherche Médicale | Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| CN118638236B (zh) * | 2024-07-09 | 2025-03-14 | 武汉爱博泰克生物科技有限公司 | 抗人cd127蛋白的抗体、抗体偶联物及其应用 |
| WO2026022216A1 (en) | 2024-07-23 | 2026-01-29 | Ose Immunotherapeutics | Uses of anti-cd127 antibodies in the treatment of inflammatory bowel diseases |
| WO2026033132A1 (en) | 2024-08-09 | 2026-02-12 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
| WO2026062296A1 (en) | 2024-09-23 | 2026-03-26 | Ose Immunotherapeutics | Therapy by antagonizing il-7 or cd127, and il-12, il-23, il-12r or il-23r |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011094259A2 (en) * | 2010-01-28 | 2011-08-04 | Glaxo Group Limited | Cd127 binding proteins |
| WO2011104687A1 (en) * | 2010-02-24 | 2011-09-01 | Rinat Neuroscience Corporation | Antagonist anti-il-7 receptor antibodies and methods |
| WO2013056984A1 (en) * | 2011-10-19 | 2013-04-25 | Effimune | Antibodies directed against the alpha chain of il7 receptor - their use for the preparation of drug candidates |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| EP2032695B1 (en) | 2006-05-31 | 2018-08-15 | The Regents of The University of California | Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs |
| ATE542830T1 (de) | 2006-12-04 | 2012-02-15 | Pasteur Institut | Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel |
| UY32038A (es) * | 2008-08-08 | 2010-03-26 | Glaxo Wellcome Mfg Pte Ltd | Inmunoblobulinas anti-cd127 y sus usos |
| WO2010085643A1 (en) | 2009-01-22 | 2010-07-29 | University Of Miami | Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders |
| EP2955196A1 (en) * | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
| KR102819051B1 (ko) | 2016-02-29 | 2025-06-12 | 오제 이뮈노테라프틱스 | Ｉｌ７ 수용체 세포외 도메인의 알파 쇄에 대해 지시된 비-길항성 항체 및 암 치료에 있어서 이의 용도 |
-
2015
- 2015-01-23 EP EP15305078.6A patent/EP2955196A1/en not_active Withdrawn
- 2015-06-10 KR KR1020177000724A patent/KR102612930B1/ko active Active
- 2015-06-10 UA UAA201613258A patent/UA125366C2/uk unknown
- 2015-06-10 SG SG11201610036PA patent/SG11201610036PA/en unknown
- 2015-06-10 US US15/317,355 patent/US10428152B2/en active Active
- 2015-06-10 WO PCT/EP2015/062993 patent/WO2015189302A1/en not_active Ceased
- 2015-06-10 MA MA040202A patent/MA40202A/fr unknown
- 2015-06-10 BR BR112016028755-0A patent/BR112016028755B1/pt active IP Right Grant
- 2015-06-10 NZ NZ726932A patent/NZ726932A/en unknown
- 2015-06-10 HK HK17104912.8A patent/HK1231487A1/zh unknown
- 2015-06-10 PE PE2016002699A patent/PE20170324A1/es unknown
- 2015-06-10 JP JP2017517406A patent/JP7324565B2/ja active Active
- 2015-06-10 CA CA2950823A patent/CA2950823A1/en active Pending
- 2015-06-10 RU RU2016151265A patent/RU2734076C2/ru active
- 2015-06-10 CN CN201580043066.1A patent/CN106715471B/zh active Active
- 2015-06-10 EP EP15727989.4A patent/EP3155014A1/en active Pending
- 2015-06-10 AU AU2015273532A patent/AU2015273532C1/en active Active
- 2015-06-10 TN TN2016000528A patent/TN2016000528A1/en unknown
- 2015-06-10 CR CR20160576A patent/CR20160576A/es unknown
- 2015-06-10 MY MYPI2016002094A patent/MY190889A/en unknown
- 2015-06-10 AP AP2016009599A patent/AP2016009599A0/en unknown
- 2015-06-10 EA EA201692460A patent/EA039303B1/ru unknown
- 2015-06-10 MX MX2016016236A patent/MX376066B/es active IP Right Grant
-
2016
- 2016-12-06 PH PH12016502445A patent/PH12016502445A1/en unknown
- 2016-12-07 IL IL249449A patent/IL249449B/en active IP Right Grant
- 2016-12-08 SA SA516380455A patent/SA516380455B1/ar unknown
- 2016-12-09 CL CL2016003172A patent/CL2016003172A1/es unknown
-
2019
- 2019-08-05 US US16/532,000 patent/US11440964B2/en active Active
-
2021
- 2021-08-05 JP JP2021128846A patent/JP2021184731A/ja active Pending
-
2022
- 2022-09-09 US US17/941,885 patent/US12371502B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011094259A2 (en) * | 2010-01-28 | 2011-08-04 | Glaxo Group Limited | Cd127 binding proteins |
| WO2011104687A1 (en) * | 2010-02-24 | 2011-09-01 | Rinat Neuroscience Corporation | Antagonist anti-il-7 receptor antibodies and methods |
| WO2013056984A1 (en) * | 2011-10-19 | 2013-04-25 | Effimune | Antibodies directed against the alpha chain of il7 receptor - their use for the preparation of drug candidates |
Non-Patent Citations (4)
| Title |
|---|
| CHUNG B. et al. Prevention of graft-versus-host disease by anti IL-7R alpha, antibody. BLOOD. October 2007, vol. 110, n. 8, pp. 2803-2810. * |
| CHUNG B. et al. Prevention of graft-versus-host disease by anti IL-7R alpha, antibody. BLOOD. October 2007, vol. 110, n. 8, pp. 2803-2810. MCALLISTER F. et al. Role of IL-17A, IL-17F and the IL-17 receptor in regulating growth-related oncogene-a and granulocyte colony-stimulating factor in bronchial epithelium: Implications for airway inflammation in cystic fibrosis. J. Immunol., vol. 175, no. 1, 1 July 2005 (2005-07-01), pp. 404-412. АЛЬТШУЛЕР E.П. и др. Получение рекомбинантных антител и способы увеличения их аффинности. Успехи биологической химии, т. 50, 2010, с. 203-258. * |
| MCALLISTER F. et al. Role of IL-17A, IL-17F and the IL-17 receptor in regulating growth-related oncogene-a and granulocyte colony-stimulating factor in bronchial epithelium: Implications for airway inflammation in cystic fibrosis. J. Immunol., vol. 175, no. 1, 1 July 2005 (2005-07-01), pp. 404-412. * |
| АЛЬТШУЛЕР E.П. и др. Получение рекомбинантных антител и способы увеличения их аффинности. Успехи биологической химии, т. 50, 2010, с. 203-258. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106715471B (zh) | 抗cd127的抗体 | |
| KR102444717B1 (ko) | 인간화 항-pacap 항체 및 그의 용도 | |
| KR101919170B1 (ko) | 중화 항-ccl20 항체 | |
| AU2015292406B2 (en) | Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same | |
| KR101601387B1 (ko) | c-KIT 항체 및 이의 용도 | |
| KR102648281B1 (ko) | 항-pacap 항체 및 그의 용도 | |
| KR101873614B1 (ko) | 항인간 수용체형 단백질 티로신 포스파타아제 σ 항체 | |
| KR102916165B1 (ko) | 중증근무력증의 치료 방법 | |
| KR20220002899A (ko) | 항-psma/cd3 항체로 전립선암을 치료하는 방법 | |
| KR20230017815A (ko) | 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편 | |
| AU2011299443A1 (en) | Anti-VEGFR-3 antibody compositions | |
| KR102903323B1 (ko) | 고양이 맥도너 육종(fms)-유사 티로신 키나제 3 수용체 리간드(flt3l)에 대한 항체 및 자가면역 및 염증 질환을 치료하기 위한 이의 용도 | |
| HK40004152B (en) | Humanized anti-pacap antibodies and uses thereof | |
| HK40004152A (en) | Humanized anti-pacap antibodies and uses thereof | |
| KR20200018643A (ko) | 면역 혈소판감소증의 치료 방법 | |
| HK1256381B (en) | Anti-pacap antibodies and uses thereof |